financetom
Business
financetom
/
Business
/
Oklo CEO Says Recent Developments Surrounding Nuclear Could Move Company Timelines Forward
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oklo CEO Says Recent Developments Surrounding Nuclear Could Move Company Timelines Forward
May 27, 2025 10:23 AM

Oklo Inc ( OKLO ) co-founder and CEO Jacob DeWitte suggested Tuesday that timelines for the company could potentially be accelerated following multiple executive orders from President Donald Trump aimed at supporting the domestic nuclear industry.

What Happened: Tuesday on CNBC’s “Money Movers,” DeWitte expressed optimism about the company’s ability to meet its projected timelines for its nuclear power facilities. He even suggested that regulatory support could allow the company to complete its goals faster than previously expected.

“Having the president sign four very significant executive orders shows a pretty big commitment of moving forward, you know, sort of these policy ideas and environment to make it so that nuclear is really going to be inevitable here in the near future,” DeWitte said.

Trump signed executive orders last week to accelerate advanced nuclear technologies in the U.S. The orders remove regulatory barriers and allow for the rebuilding of a secure domestic nuclear fuel supply chain.

Check This Out: Uranium Mining Stocks Rally After Trump’s Nuclear Revival Order Ignites Industry Optimism

Oklo ( OKLO ) also announced a deal on Tuesday with Korea Hydro & Nuclear Power to collaborate on the development and global deployment of Oklo’s advanced nuclear technology. DeWitte told CNBC that the company has a phenomenal track record of being able to deliver on time and on budget.

The Oklo ( OKLO ) CEO said the deal is going to be “accelerative” for the company both domestically and abroad. Oklo ( OKLO ) has laid out timelines for deployment of its first nuclear plant in late 2027 or early 2028, but the executive orders combined with the company’s new collaboration could speed up those timelines.

He told CNBC that the recent flurry of news on the nuclear front has created an environment “that makes it possible to think even more boldly than what we’re aiming for.”

“We’ll see, the executive orders obviously are fresh. That opens the door to do things a little bit differently and in new ways perhaps, so we’re evaluating those and those impacts, but it’s possible there could be some things that either help firm up those timelines or even move them forward, which would be pretty amazing,” DeWitte said.

Nuclear power development has faced significant delays as safety concerns arose following major incidents at global reactor sites, but the need for more power has become increasingly evident as new technologies like AI rapidly increase energy demands.

“All of that is going to require a significant frankly nuclear footprint in the country and people see that increasingly. Also people are getting more and more comfortable with the technology,” DeWitte said.

Oklo ( OKLO ) said earlier this month that it's nearing submission of the Oklo Fuel Foundry LPP to the Nuclear Regulatory Commission, which is the next step in the licensing process for the company’s commercial fuel fabrication facility. Oklo ( OKLO ) also recently announced completion of borehole drilling for site characterization work at the Idaho National Laboratory site, the location for the company's first planned Aurora Powerhouse. 

OKLO Price Action: Oklo ( OKLO ) shares jumped 23% on Friday following the nuclear-related executive orders. Shares continued to move higher Tuesday morning on the deal with Korea Hydro & Nuclear Power, and then surged to session highs as DeWitte talked timelines on CNBC. Oklo ( OKLO ) stock was up 7.69% at $52.65 at the time of publication on Tuesday, according to Benzinga Pro.

Read Next:

Nvidia’s Q1 Earnings Loom, While AMD’s Edge AI Bet Could Change The Narrative

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Maersk faces significant port congestion in Asia, Mediterranean
Maersk faces significant port congestion in Asia, Mediterranean
Jun 3, 2024
OSLO (Reuters) - Maersk faces significant terminal congestion in Mediterranean and Asian ports, causing substantial delays in its vessel schedule, the Danish shipping group said in a statement on Monday. As a result of the congestion, the company will skip two westbound sailings from China and South Korea that had been planned to depart in early July, it added. ...
GameStop Nearly Doubles, AMC Soars 30% Premarket: What's Setting Meme Stocks On Fire Again?
GameStop Nearly Doubles, AMC Soars 30% Premarket: What's Setting Meme Stocks On Fire Again?
Jun 3, 2024
Shares of GameStop Corp ( GME ). and AMC Entertainment Holdings, Inc. ( AMC ) , which had cooled off after a hot rally in mid-May, are surging higher in premarket trading on Monday. The resumption of the meme rally came on the back of Keith Gill, also known as “Roaring Kitty,” disclosing a substantial position in GameStop ( GME...
S&P Global's Platts Launches New Daily Assessments of Poultry, Beef Prices
S&P Global's Platts Launches New Daily Assessments of Poultry, Beef Prices
Jun 3, 2024
04:43 AM EDT, 06/03/2024 (MT Newswires) -- Platts said Monday it has launched new daily bulk-market price assessments for poultry and beef markets in the Americas, Asia, and the Middle East. The Standard & Poor's (SPGI) Global Commodity Insights company said the assessments will be accessible through the newly launched platform Platts Protein Daily. The publication includes a mix of...
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients
Jun 3, 2024
04:32 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 trial showed its Imfinzi drug reducing the risk of death by 27% versus placebo in patients with limited-stage small-cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy. The company said the drug, also known as durvalumab, is the first and only immunotherapy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved